Optimization and Evaluation of Al18F Labeling Using a NOTA—or RESCA1-Conjugated AE105 Peptide Antagonist of uPAR

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Optimization and Evaluation of Al18F Labeling Using a NOTA—or RESCA1-Conjugated AE105 Peptide Antagonist of uPAR. / Jeppesen, Troels E.; Simón, Marina; Torp, Josephine; Knudsen, Line B. S.; Leth, Julie Maja; Crestey, François; Ploug, Michael; Jørgensen, Jesper T.; Madsen, Jacob; Herth, Matthias M.; Kjaer, Andreas.

I: Frontiers in Nuclear Medicine, Bind 1, 799533, 2021.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Jeppesen, TE, Simón, M, Torp, J, Knudsen, LBS, Leth, JM, Crestey, F, Ploug, M, Jørgensen, JT, Madsen, J, Herth, MM & Kjaer, A 2021, 'Optimization and Evaluation of Al18F Labeling Using a NOTA—or RESCA1-Conjugated AE105 Peptide Antagonist of uPAR', Frontiers in Nuclear Medicine, bind 1, 799533. https://doi.org/10.3389/fnume.2021.799533

APA

Jeppesen, T. E., Simón, M., Torp, J., Knudsen, L. B. S., Leth, J. M., Crestey, F., Ploug, M., Jørgensen, J. T., Madsen, J., Herth, M. M., & Kjaer, A. (2021). Optimization and Evaluation of Al18F Labeling Using a NOTA—or RESCA1-Conjugated AE105 Peptide Antagonist of uPAR. Frontiers in Nuclear Medicine, 1, [799533]. https://doi.org/10.3389/fnume.2021.799533

Vancouver

Jeppesen TE, Simón M, Torp J, Knudsen LBS, Leth JM, Crestey F o.a. Optimization and Evaluation of Al18F Labeling Using a NOTA—or RESCA1-Conjugated AE105 Peptide Antagonist of uPAR. Frontiers in Nuclear Medicine. 2021;1. 799533. https://doi.org/10.3389/fnume.2021.799533

Author

Jeppesen, Troels E. ; Simón, Marina ; Torp, Josephine ; Knudsen, Line B. S. ; Leth, Julie Maja ; Crestey, François ; Ploug, Michael ; Jørgensen, Jesper T. ; Madsen, Jacob ; Herth, Matthias M. ; Kjaer, Andreas. / Optimization and Evaluation of Al18F Labeling Using a NOTA—or RESCA1-Conjugated AE105 Peptide Antagonist of uPAR. I: Frontiers in Nuclear Medicine. 2021 ; Bind 1.

Bibtex

@article{3f585461da3f44b98213dec939f05a97,
title = "Optimization and Evaluation of Al18F Labeling Using a NOTA—or RESCA1-Conjugated AE105 Peptide Antagonist of uPAR",
abstract = "Fluorine-18 displays almost ideal decay properties for positron emission tomography (PET) and allows for large scale production. As such, simplified methods to radiolabel peptides with fluorine-18 are highly warranted. Chelation of aluminium fluoride-18 toward specific peptides represents one method to achieve this. With the current methods, chelation of aluminium fluoride-18 can be achieved using NOTA-conjugated peptides. However, the heating to 90–100◦C that is required for this chelation approach may be deleterious to the targeting moiety of the probe. Recently, a new chelator, RESCA1, was developed allowing Al18F chelation at room temperature. Here, we optimize the labeling procedure enabling high chelation efficacy of fluoride-18 at 22◦C, even at full batch labeling. The optimized procedure was tested by Al18F-labeling of RESCA1-AE105—a uPAR targeting peptide. NOTA-AE105 was also labeled with Al18F, and the two peptides were compared head-to-head. [18F]AlF-NOTA-AE105 and [18F]AlF-RESCA1-AE105 could be produced in equal radiochemical yields (RCY), radiochemical purities (RCP) and molar activities. Additionally, the two peptides showed comparable binding affinity to uPAR and uptake in cells expressing the uPAR, when evaluated in vitro. Overall, we found that the performances of [18F]AlF-NOTA-AE105 and [18F]AlF-RESCA1-AE105 were grossly comparable, but importantly RESCA1 can be labeled with aluminium fluoride-18 at 22◦C. Consequently, this study showed that RESCA1 is superior to NOTA with respect to Al18F chelation of temperature sensitive molecules, such as thermolabile peptides and proteins as well as that full batch chelation of RESCA1 with fluoride-18 is possible.",
author = "Jeppesen, {Troels E.} and Marina Sim{\'o}n and Josephine Torp and Knudsen, {Line B. S.} and Leth, {Julie Maja} and Fran{\c c}ois Crestey and Michael Ploug and J{\o}rgensen, {Jesper T.} and Jacob Madsen and Herth, {Matthias M.} and Andreas Kjaer",
year = "2021",
doi = "10.3389/fnume.2021.799533",
language = "English",
volume = "1",
journal = "Frontiers in Nuclear Medicine",
issn = "2673-8880",
publisher = "Frontiers Media",

}

RIS

TY - JOUR

T1 - Optimization and Evaluation of Al18F Labeling Using a NOTA—or RESCA1-Conjugated AE105 Peptide Antagonist of uPAR

AU - Jeppesen, Troels E.

AU - Simón, Marina

AU - Torp, Josephine

AU - Knudsen, Line B. S.

AU - Leth, Julie Maja

AU - Crestey, François

AU - Ploug, Michael

AU - Jørgensen, Jesper T.

AU - Madsen, Jacob

AU - Herth, Matthias M.

AU - Kjaer, Andreas

PY - 2021

Y1 - 2021

N2 - Fluorine-18 displays almost ideal decay properties for positron emission tomography (PET) and allows for large scale production. As such, simplified methods to radiolabel peptides with fluorine-18 are highly warranted. Chelation of aluminium fluoride-18 toward specific peptides represents one method to achieve this. With the current methods, chelation of aluminium fluoride-18 can be achieved using NOTA-conjugated peptides. However, the heating to 90–100◦C that is required for this chelation approach may be deleterious to the targeting moiety of the probe. Recently, a new chelator, RESCA1, was developed allowing Al18F chelation at room temperature. Here, we optimize the labeling procedure enabling high chelation efficacy of fluoride-18 at 22◦C, even at full batch labeling. The optimized procedure was tested by Al18F-labeling of RESCA1-AE105—a uPAR targeting peptide. NOTA-AE105 was also labeled with Al18F, and the two peptides were compared head-to-head. [18F]AlF-NOTA-AE105 and [18F]AlF-RESCA1-AE105 could be produced in equal radiochemical yields (RCY), radiochemical purities (RCP) and molar activities. Additionally, the two peptides showed comparable binding affinity to uPAR and uptake in cells expressing the uPAR, when evaluated in vitro. Overall, we found that the performances of [18F]AlF-NOTA-AE105 and [18F]AlF-RESCA1-AE105 were grossly comparable, but importantly RESCA1 can be labeled with aluminium fluoride-18 at 22◦C. Consequently, this study showed that RESCA1 is superior to NOTA with respect to Al18F chelation of temperature sensitive molecules, such as thermolabile peptides and proteins as well as that full batch chelation of RESCA1 with fluoride-18 is possible.

AB - Fluorine-18 displays almost ideal decay properties for positron emission tomography (PET) and allows for large scale production. As such, simplified methods to radiolabel peptides with fluorine-18 are highly warranted. Chelation of aluminium fluoride-18 toward specific peptides represents one method to achieve this. With the current methods, chelation of aluminium fluoride-18 can be achieved using NOTA-conjugated peptides. However, the heating to 90–100◦C that is required for this chelation approach may be deleterious to the targeting moiety of the probe. Recently, a new chelator, RESCA1, was developed allowing Al18F chelation at room temperature. Here, we optimize the labeling procedure enabling high chelation efficacy of fluoride-18 at 22◦C, even at full batch labeling. The optimized procedure was tested by Al18F-labeling of RESCA1-AE105—a uPAR targeting peptide. NOTA-AE105 was also labeled with Al18F, and the two peptides were compared head-to-head. [18F]AlF-NOTA-AE105 and [18F]AlF-RESCA1-AE105 could be produced in equal radiochemical yields (RCY), radiochemical purities (RCP) and molar activities. Additionally, the two peptides showed comparable binding affinity to uPAR and uptake in cells expressing the uPAR, when evaluated in vitro. Overall, we found that the performances of [18F]AlF-NOTA-AE105 and [18F]AlF-RESCA1-AE105 were grossly comparable, but importantly RESCA1 can be labeled with aluminium fluoride-18 at 22◦C. Consequently, this study showed that RESCA1 is superior to NOTA with respect to Al18F chelation of temperature sensitive molecules, such as thermolabile peptides and proteins as well as that full batch chelation of RESCA1 with fluoride-18 is possible.

U2 - 10.3389/fnume.2021.799533

DO - 10.3389/fnume.2021.799533

M3 - Journal article

VL - 1

JO - Frontiers in Nuclear Medicine

JF - Frontiers in Nuclear Medicine

SN - 2673-8880

M1 - 799533

ER -

ID: 344851376